Information  X 
Enter a valid email address

Vanguard Medica (VER)

  Print      Mail a friend       Annual reports

Wednesday 26 January, 2000

Vanguard Medica

New R&D Advisory Panel

Vanguard Medica Group PLC
26 January 2000

                   Vanguard announces new R&D Advisory Panel
Guildford, UK, 26 January 2000, Vanguard Medica Group plc (LSE:VGD)
('Vanguard' or the 'Company') today announced a new Research & Development
Advisory Panel, which will be chaired by Sir Mark Richmond.

Sir Mark has enjoyed both an outstanding academic career and a number of
senior positions in international pharmaceutical companies including a period
as Head of Research Worldwide for Glaxo in the mid 1990's.  He is a fellow of
the Royal Society and a special adviser and non-executive director to a number
of pharmaceutical and biotechnology companies, including Genentech.  He is
Chairman of Cancer Research Campaign Technology ('CRCT') and of Cancer
Research  Ventures ('CRV'), the development collaboration set up in August
1999 with Vanguard.

The core panel comprises Sir Mark Richmond, Sir William Asscher, Dr Roger
Brimblecombe, Dr Marvin Jaffe and Dr Charles Smith. This Group will meet
regularly with international experts in CNS and oncology to call upon their
specialist expertise.

Robert Mansfield, Chief Executive Officer of Vanguard commented:

 'We believe our advisory panel has an extremely important role to play in the
strategic development of the Company and in the building of future shareholder
value.  We are delighted to have an R&D Advisory Panel of such outstanding
quality and we look forward to working with them on the development of our
existing R&D portfolio and on the addition of further innovative projects in
the future.'


Vanguard Medica Group plc
Robert Mansfield    Chief Executive Officer                      01483-787-878

Anne Gilding        Head of Corporate Communications             01483-787-817

Gavin Anderson & Company
(on behalf of Vanguard Medica)
Philip Ward                                                      0171-457-2345

For previous press releases please see Vanguard's website:
Vanguard Medica
Vanguard Medica, an emerging pharmaceutical company, was established in 1991
and floated on the London Stock Exchange in 1996.  Following the acquisition
of Cerebrus Pharmaceuticals Limited in December 1999, and its collaboration
with the Cancer Research Ventures (CRV), announced in August 1999, the
Company's strategy is moving to a focus on opportunities primarily in CNS and

Vanguard currently has four compounds in its development portfolio.
Frovatriptan, an acute oral treatment for migraine, is the most advanced of
the compounds and is scheduled to reach the European markets by late 2000.
Vanguard has agreements with Menarini to market the drug throughout Europe and
with Elan for commercialisation in North America.

Vanguard's other development projects include an oral asthma treatment, an
endothelin antagonist for the treatment of sub-arachnoid haemorrhage and the
prevention of acute renal failure, an immune response modifier for the
treatment of hepatitis C and a 5HT1A receptor agonist for chemotherapy-induced
emesis.  Following a strategic review of the newly merged businesses in Q1
2000 the Company's strategy will be to build on its existing development
capability and to capitalise on the Company's valuable intellectual property
assets in the Cerebrus research portfolio.  These are predominantly in late
stage research or early pre-clinical development and include projects in
obesity, Parkinson's disease, stroke, anxiety and pain.  In December 1999 a
major new collaboration with Roche was announced on the obesity research

The newly merged organisation intends to change its name to Vernalis later
this year.